Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Q1 2023 Results Conference Call May 11, 2023 8:30 AM ET

Company Participants

Sasha Damouni Ellis - Vice President of Corporate Affairs and Investor Relations

Scott Braunstein - Chairman and Chief Executive Officer

Christy Shafer - Chief Commercial Officer

Alex Aimetti - Chief Scientific Officer

Steven Pfanstiel - Chief Financial Officer and Chief Operating Officer

Michael Dougherty - Director

Conference Call Participants

Andrew Tsai - Jefferies

Charles Duncan - Cantor Fitzgerald

Brian Abrahams - RBC Capital Markets

Joseph Thome - TD Cowen

Douglas Tsao - H.C. Wainwright

Brian Skorney - Baird

Joon Lee - Truist Securities

Mark Goodman - SVB Securities

Jay Olson - Oppenheimer

Michael Higgins - Ladenburg Thalmann

Operator

Greetings and welcome to the Marinus Pharmaceuticals’ First Quarter 2023 Financial Results and Business Update Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session.

And now it is my pleasure to introduce your host, Sasha Damouni Ellis, Vice President of Corporate Affairs and Investor Relations. You may begin Ms. Damouni Ellis.

Sasha Damouni Ellis

Thank you and good morning. With me from Marinus Pharmaceuticals are Dr. Scott Braunstein, Chairman and Chief Executive Officer; Christy Shafer, Chief Commercial Officer; Dr. Alex Aimetti, Chief Scientific Officer; and Steve Pfanstiel, Chief Financial Officer and Chief Operating Officer.

Before we begin, I would like to remind everyone that some of the statements we are making today are Forward-Looking Statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by such forward-looking statements. These risks and uncertainties and risks associated with our business are described in the Company’s reports filed with the Securities and Exchange Commission including Form 10-K, 10-Q and 8-K.

I will now turn the call over to our CEO, Scott Braunstein.

Scott Braunstein

Thank you, Sasha and welcome to our call. During the first quarter of 2023, we made important progress advancing our oral and IV Ganaxolone programs further establishing Marinus as a leader in the development of innovative treatment options for patients with rare genetic epilepsy and refractory seizure disorders.

We continue to make considerable strides with the launch of ZTALMY, are pleased with our first quarter sales of $3.3 million and are on-track to meet our previously stated full-year 2023 guidance of $15 million to $17 million. Christy Shafer, our Chief Commercial Officer will be reviewing some of the key initiatives for 2023 that we believe will support the continued growth of ZTALMY.